Table 3.
Most prevalently mutated non-BRCA1/2 genes in BRCA1/2-mutated patients (evaluable ITT population)a.
| Gene mutations | Cohort 1 (n = 29) | Cohort 2 (n = 28) | Total Cohorts 1 and 2 (N = 57) |
|---|---|---|---|
| Copy number alterations excluded (%) | |||
| TP53 | |||
| BRCA1 | 88.2 | 58.3 | 75.9 |
| BRCA2 | 8.3 | 18.8 | 14.3 |
| BRCA1/2 | 55.2 | 35.7 | 45.6 |
| PIK3CA | |||
| BRCA1 | 5.9 | 0.0 | 3.4 |
| BRCA2 | 16.7 | 18.8 | 17.9 |
| BRCA1/2 | 10.3 | 10.7 | 10.5 |
| Copy number alterations only (%) | |||
| RAD21 | |||
| BRCA1 | 17.6 | 41.7 | 27.6 |
| BRCA2 | 25.0 | 43.8 | 35.7 |
| BRCA1/2 | 20.7 | 42.9 | 31.6 |
| MYC | |||
| BRCA1 | 11.8 | 33.3 | 20.7 |
| BRCA2 | 8.3 | 12.5 | 10.7 |
| BRCA1/2 | 10.3 | 21.4 | 15.8 |
Cohort 1 comprised patients with response to prior platinum and no progression within 8 weeks and Cohort 2 comprised patients who received ≥3 platinum-free cytotoxic regimens.
BRCA1/2 breast cancer susceptibility gene 1 or 2, ITT intent-to-treat.
aEvaluable ITT population includes all patients with tumor samples suitable for the genomic evaluation and analyzed using FoundationOne® CDx who have BRCA1/2 mutations (known or likely pathogenic impact, excluding copy number alterations). Genes shown are mutated in ≥10% of patients in combined cohorts.